GSK plans $100M makeover of US man­u­fac­tur­ing site; La Jol­la Phar­ma gets a 'break­through' with late-stage drug

→ GSK $GSK an­nounced to­day that it will be in­vest­ing $100 mil­lion in­to its fa­cil­i­ty in Hamil­ton, MT to ex­pand long-term vac­cine man­u­fac­tur­ing ca­pa­bil­i­ties. The ex­pan­sion will boost pro­duc­tion ca­pac­i­ty of key com­po­nents of the ad­ju­vant sys­tem used in sev­er­al of its vac­cines and fos­ter new jobs, in­clud­ing tem­po­rary con­struc­tion and var­i­ous per­ma­nent po­si­tions like sci­en­tists, en­gi­neers and man­u­fac­tur­ing and qual­i­ty pro­fes­sion­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER